Insulin and insulin-like growth factor I are known to be mitogenic and therefore may play a role in the development of endometrial cancer. We undertook this study to investigate whether human endometrial cancer tissue has receptors for these substances. Endometrial cancer tissue samples were obtained at hysterectomy from 10 women with endometrial cancer, and control endometrial tissue was collected from normal cycling women undergoing hysterectomy for nonendocrine problems. Binding studies with iodine 125-insulin and [125I]insulin-like growth factor I revealed the presence of specific binding sites for insulin and insulin-like growth factor I in both normal endometrium and endometrial cancer tissue. The percent binding of [125I]insulin in the endometrial cancer tissue (mean +/- SE 2.4% +/- 0.5%/100 micrograms protein) was not significantly different from that in normal endometrium (3.5% +/- 1%/100 micrograms protein). On the contrary, the percent total binding of [125]insulin-like growth factor I in the endometrial cancer (5.3% +/- 1.5%/100 micrograms protein) was significantly (p less than 0.04) higher than that observed in normal endometrium (2.1% +/- 0.4%/100 micrograms protein). There was a significant positive correlation between the histologic grade of the tumor and the insulin-like growth factor I binding (r = 0.865, p less than 0.02). The affinity constants for the high-affinity receptors were similar in the normal and neoplastic endometrium. These results indicate that insulin and insulin-like growth factor I may play a role in the growth and development of endometrial cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0002-9378(91)90047-uDOI Listing

Publication Analysis

Top Keywords

endometrial cancer
36
growth factor
28
insulin-like growth
20
insulin insulin-like
16
cancer tissue
16
micrograms protein
16
normal endometrium
12
endometrial
10
cancer
9
specific binding
8

Similar Publications

Development and Validation of a Nomogram Based on Multiparametric MRI for Predicting Lymph Node Metastasis in Endometrial Cancer: A Retrospective Cohort Study.

Acad Radiol

December 2024

Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China (Y.T., Y.W., Y.Y., X.Q., Y.H., J.L.); Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education, Nanning 530021, Guangxi Zhuang Autonomous Region, PR China (J.L.). Electronic address:

Rationale And Objectives: To develop a radiomics nomogram based on clinical and magnetic resonance features to predict lymph node metastasis (LNM) in endometrial cancer (EC).

Materials And Methods: We retrospectively collected 308 patients with endometrial cancer (EC) from two centers. These patients were divided into a training set (n=155), a test set (n=67), and an external validation set (n=86).

View Article and Find Full Text PDF

Clinical and histopathological evaluation of patients with endometrial cancer in a University Hospital: Seven-year experience.

Malays J Pathol

December 2024

Universiti Sains Malaysia, School of Medical Sciences, Department of Obstetrics & Gynaecology, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia.

Introduction: Endometrial cancer is one of the leading gynaecological malignancies in developed countries and becoming more prevalent in Malaysia. These have significant impact in women and management of this disease. If it occurs on young women, and as a whole becomes a burden on the national economy and world.

View Article and Find Full Text PDF

Background: Mitochondrial transcription elongation factor (TEFM) is a recently discovered factor involved in mitochondrial DNA replication and transcription. Previous studies have reported that abnormal TEFM expression can disrupt the assembly of mitochondrial respiratory chain and thus mitochondrial function. However, the role of TEFM on Uterine corpus endometrial carcinoma (UCEC) progression remains unclear.

View Article and Find Full Text PDF

Endometrial cancer is the most prevalent form of gynecologic malignancy, with a significant surge in incidence among youngsters. Although the advent of the immunotherapy era has profoundly improved patient outcomes, not all patients benefit from immunotherapy; some patients experience hyperprogression while on immunotherapy. Hence, there is a pressing need to further delineate the distinct immune response profiles in patients with endometrial cancer to enhance prognosis prediction and facilitate the prediction of immunotherapeutic responses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!